Browse studies

Find your next paid study

5 recruiting studies matching your filters

A Single Arm Open-Label Pilot Study to Investigate the Safety and Clinical Activity of Cemiplimab, A Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients With Incurable NUT Carcinoma (NC)

This phase II trial studies how well cemiplimab works in treating patients with nuclear protein of testis (NUT) carcinoma for which no treatment is currently a…

Metastatic NUT CarcinomaUnresectable NUT Carcinoma

Estimated

~$10 – $6,250

Northwestern UniversityNCT07050186

Phase 1

A Phase 1 Study of BET Bromodomain Inhibitor ZEN003694 in Combination With the CDK4/6 Inhibitor Abemaciclib in Patients With NUT Carcinoma, Breast Cancer and Other Solid Tumors

This phase I trial tests the safety, side effects, and best dose of ZEN003694 when given together with abemaciclib in treating patients with NUT carcinoma, bre…

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+5 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05372640

Phase 1

A Phase 1 Study of the Bromodomain Inhibitor ZEN003694 in Combination With Platinum-based Chemotherapy in Patients With NUT Carcinoma

This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with cisplatin and etoposide or carboplatin and paclitaxel in trea…

Advanced NUT CarcinomaMetastatic NUT CarcinomaUnresectable NUT Carcinoma

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05019716

Phase 1

A Phase 1 Study of EP31670, a Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies

Castrate Resistant Prostate CancerNUT CarcinomaChronic Myelomonocytic Leukemia+1 more

Estimated

~$10 – $8,750

Epigenetix, Inc.NCT05488548

Biology of Young Lung Cancer Study: The YOUNG LUNG Study

The purpose of this research study is to learn more about lung cancer (NSCLC or SCLC) diagnosed in adults at ages 45 or younger.

Non Small Cell Lung CancerSmall Cell Lung CarcinomaNUT Carcinoma

Estimated

~$10 – $1,125

Dana-Farber Cancer InstituteNCT05265429